Venkatesh Chellappa

Venkatesh Chellappa

Auto-generated profile, based on publicly available information

Venkatesh Chellappa

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in European Urology Focus
Verified
Journal Article
Open access
AMAshkan Mortezavi
Ashkan Mortezavi
TPThorgerdur Palsdottir
Thorgerdur Palsdottir
MEMartin Eklund
Martin Eklund
VCVenkatesh Chellappa
Venkatesh Chellappa
SMSarath Kumar Murugan
Sarath Kumar Murugan
TNTobias Nordström
Tobias Nordström
A new generation of risk calculators (RCs) for prostate cancer (PCa) incorporating magnetic resonance imaging (MRI) data have been introduced. However, these have not been validated externally, and their clinical benefit compared with alternative approaches remains unclear. To assess previously published PCa RCs incorporating MRI data, and compare their performance with traditional RCs (European Randomized Study of Screening for Prostate Cancer [ERSPC] 3/4 and Prostate Biopsy Collaborative Group [PBCG]) and the blood-based Stockholm3 test. RCs were tested in a prospective multicenter cohort including 532 men aged 45-74 yr participating in the Stockholm3-MRI study between 2016 and 2017. The probabilities of detection of clinically significant PCa (csPCa) defined as Gleason score ≥3 + 4 were calculated for each patient. For each RC and the Stockholm3 test, discrimination was assessed by area under the curve (AUC), calibration by numerical and graphical summaries, and clinical usefulness by decision curve analysis (DCA). The discriminative ability of MRI RCs 1-4 for the detection of csPCa was superior (AUC 0.81-0.87) to the traditional RCs (AUC 0.76-0.80). The observed prevalence of csPCa in the cohort was 37%, but calibration-in-the-large predictions varied from 14% to 63% across models. DCA identified only one model including MRI data as clinically useful at a threshold probability of 10%. The Stockholm3 test achieved equivalent performance for discrimination (AUC 0.86) and DCA, but was underpredicting the actual risk. Although MRI RCs discriminated csPCa better than traditional RCs, their predicted probabilities were variable in accuracy, and DCA identified only one model as clinically useful. Novel risk calculators (RCs) incorporating imaging improved the ability to discriminate clinically significant prostate cancer compared with traditional tools. However, all but one predicted divergent compared with actual risks, suggesting that regional modifications be implemented before usage. The Stockholm3 test achieved performance comparable with the best MRI RC without utilization of imaging.

4 April 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
IÖIngegerd Öfverholm
Ingegerd Öfverholm
KWKarin Wallander
Karin Wallander
CHCecilia Haglund
Cecilia Haglund
VCVenkatesh Chellappa
Venkatesh Chellappa
JWJohan Wejde
Johan Wejde
FHFelix Haglund
Felix Haglund
Purpose: Tumor classification is a key component in personalized cancer care. For soft-tissue and bone tumors, this classification is currently based primarily on morphology assessment and IHC staining. However, these standard-of-care methods can pose challenges for pathologists. We therefore assessed how whole-genome and whole-transcriptome sequencing (WGTS) impacted tumor classification and clinical management when interpreted together with histomorphology. Experimental Design: We prospectively evaluated WGTS in routine diagnostics of 200 soft-tissue and bone tumors suspicious for malignancy, including DNA and RNA isolation from the tumor, and DNA isolation from a peripheral blood sample or any non-tumor tissue. Results: On the basis of specific genomic alterations or absence of presumed findings, WGTS resulted in reclassification of 7% (13/197) of the histopathologic diagnoses. Four cases were downgraded from low-grade sarcomas to benign lesions, and two cases were reclassified as metastatic malignant melanomas. Fusion genes associated with specific tumor entities were found in 30 samples. For malignant soft-tissue and bone tumors, we identified treatment relevant variants in 15% of cases. Germline pathogenic variants associated with a hereditary cancer syndrome were found in 22 participants (11%). Conclusions: WGTS provides an important dimension of data that aids in the classification of soft-tissue and bone tumors, correcting a significant fraction of clinical diagnoses, and identifies molecular targets relevant for precision medicine. However, genetic findings need to be evaluated in their morphopathologic context, just as germline findings need to be evaluated in the context of patient phenotype and family history.

14 June 2024
Verified
Other
Open access
IÖIngegerd Öfverholm
Ingegerd Öfverholm
KWKarin Wallander
Karin Wallander
CHCecilia Haglund
Cecilia Haglund
VCVenkatesh Chellappa
Venkatesh Chellappa
JWJohan Wejde
Johan Wejde
FHFelix Haglund
Felix Haglund
Supplementary Data 8 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma

14 June 2024
Verified
Other
Open access
IÖIngegerd Öfverholm
Ingegerd Öfverholm
KWKarin Wallander
Karin Wallander
CHCecilia Haglund
Cecilia Haglund
VCVenkatesh Chellappa
Venkatesh Chellappa
JWJohan Wejde
Johan Wejde
FHFelix Haglund
Felix Haglund
Supplementary Figure 1 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma

14 June 2024
Verified
Other
Open access
IÖIngegerd Öfverholm
Ingegerd Öfverholm
KWKarin Wallander
Karin Wallander
CHCecilia Haglund
Cecilia Haglund
VCVenkatesh Chellappa
Venkatesh Chellappa
JWJohan Wejde
Johan Wejde
FHFelix Haglund
Felix Haglund
Supplementary Data 9 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma

14 June 2024
Verified
Other
Open access
IÖIngegerd Öfverholm
Ingegerd Öfverholm
KWKarin Wallander
Karin Wallander
CHCecilia Haglund
Cecilia Haglund
VCVenkatesh Chellappa
Venkatesh Chellappa
JWJohan Wejde
Johan Wejde
FHFelix Haglund
Felix Haglund
Supplementary Data 3 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma